FDA approves Roche's Gazyva for primary membranous nephropathy
The FDA approved Gazyva for adults with primary membranous nephropathy at risk of progression, the disease’s first FDA-approved treatment; in a phase III trial, 36.1% of patients achieved complete proteinuria remission at two years, versus 5.7% with tacrolimus.





